đŸ”Ĩ 42 IAS Prelims 2026 Questions Themes Came Directly from Our Expected Topics. Click for the Proof. đŸ”Ĩ Admissions Open for 21st September GS Batch. Register Now.

What is CBFC?

What is CBFC?

Important for GS Prelims: Governance About Legal Basis Composition Film Certification Categories Certificate Meaning U Unrestricted public exhibition. UA 7+ […]

āĻ…āύ⧁āĻšā§āϛ⧇āĻĻ ā§§ā§Ŧ (Article 16) āϕ⧀?

What is Article 16

UPSC āĻĒā§āϰāĻŋāϞāĻŋāĻŽāϏ⧇āϰ āϜāĻ¨ā§āϝ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ – āϰāĻžāĻˇā§āĻŸā§āϰāĻŦāĻŋāĻœā§āĻžāĻžāύ (Polity) āĻ“ āϏ⧁āĻļāĻžāϏāύ (Governance) āĻ…āύ⧁āĻšā§āϛ⧇āĻĻ ā§§ā§Ŧ (Article 16) – āĻāϟāĻŋ āϕ⧀? āĻ…āύ⧁āĻšā§āϛ⧇āĻĻ ā§§ā§Ŧ-āĻāϰ āĻĒā§āϰāϧāĻžāύ […]

What is Article 16

What is Article 16

Important for UPSC Prelims – Polity & Governance Article 16 (What is it?) Key Provisions of Article 16 1. Article […]

CBSE āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻŦāĻŋāϤāĻ°ā§āĻ• (CBSE Evaluation Controversy) āĻŽā§‹āĻ•āĻžāĻŦāĻŋāϞāĻžāϝāĻŧ āϕ⧀ āĻ•āϰāĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇?

What can be done to address the CBSE Evaluation Controversy?

āĻāχ āύāĻŋāĻŦāĻ¨ā§āϧāϟāĻŋ āĻĒāĻĄāĻŧāĻžāϰ āĻĒāϰ āφāĻĒāύāĻŋ āύāĻŋāĻŽā§āύāϞāĻŋāĻ–āĻŋāϤ UPSC āĻŽā§‡āχāύāϏ āĻŽāĻĄā§‡āϞ āĻĒā§āϰāĻļā§āύ⧇āϰ āωāĻ¤ā§āϤāϰ āϞāĻŋāĻ–āϤ⧇ āĻĒāĻžāϰāĻŦ⧇āύ: Digitalisation of examination evaluation can improve efficiency, […]

āĻŸā§‡āĻ•āϏāχ āĻĒāϰāĻŋāĻŦāĻšāύ⧇āϰ āĻĒāĻĨ⧇ āĻ­āĻžāϰāϤ: Draft CAFE III Norms-āĻāϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦ āĻ“ āĻšā§āϝāĻžāϞ⧇āĻžā§āϜ

Transitioning to Sustainable Mobility: Evaluating India’s Draft CAFE III Norms

āĻāχ āφāĻ°ā§āϟāĻŋāϕ⧇āϞ āĻĒāĻĄāĻŧ⧇ āφāĻĒāύāĻŋ UPSC Mains-āĻāϰ āĻāχ āĻĒā§āϰāĻļā§āύāϟāĻŋāϰ āωāĻ¤ā§āϤāϰ āϞāĻŋāĻ–āϤ⧇ āĻĒāĻžāϰāĻŦ⧇āύ: Corporate Average Fuel Efficiency (CAFE) III Norms-āĻāϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦ āĻāĻŦāĻ‚ […]

LAG-3-āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• Dual Immunotherapy (RELOPDUO): āĻ•ā§āϝāĻžāύāϏāĻžāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϝāĻŧ āĻāĻ•āϟāĻŋ āύāϤ⧁āύ āĻĒāĻĻā§āϧāϤāĻŋ

LAG-3-based Dual Immunotherapy (RELOPDUO): A New Approach in Cancer Treatment.

āĻĒā§āϰāϏāĻ™ā§āĻ— Immunotherapy āϕ⧀? Dual Immunotherapy āϕ⧀? LAG-3 āϕ⧀? RELOPDUO āϕ⧀? Q. LAG-3-āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• Dual Immunotherapy āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āύāĻŋāĻšā§‡āϰ āĻŦāĻ•ā§āϤāĻŦā§āϝāϗ⧁āϞāĻŋ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰ⧁āύ:1. LAG-3 […]